2 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMORecruiting
Study Objectives:The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK),pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients withthrombotic microangiopathies (TMA) following…